Filing Flows

Filing Flows › Companies › Inhibrx Biosciences › Report card

Inhibrx Biosciences earnings report card

Every report on file against what analysts and the company itself expected, and what the stock did

Beat rate0 of 4 reports beat the EPS estimate

Inhibrx Biosciences (INBX) beat the analysts' EPS estimate in 0 of its last 4 reports (0%), by -28.9% on average. Next report: Nov 13, 2026, analysts expect EPS −$2.35.

Beat rate0% of 4
Average surprise-28.9%
Next reportNov 13, 2026

Report by report

QuarterReportedEPS est.EPS reportedSurpriseGAAP EPS
Q to Jun 2026Aug 13, 2026−$2.28−$2.34-2.6%−$2.34
Q to Mar 2026May 14, 2026−$1.20−$2.15-79.2%−$2.15
Q to Dec 2025Mar 19, 2026−$2.08−$2.11-1.4%—
Q to Sep 2025Nov 14, 2025−$1.72−$2.28-32.6%−$2.28

Estimates and reported EPS are the Street's adjusted figures; GAAP EPS is from the filing (SEC XBRL). No daily prices are on file for these report days, so the stock's moves are not shown.

Charts

Inhibrx Biosciences: EPS reported against the estimateInhibrx Biosciences: EPS reported against the estimateEstimateReported−$1.72−$2.28Q to Sep 20…−$2.08−$2.11Q to Dec 20…−$1.20−$2.15Q to Mar 20…−$2.28−$2.34Q to Jun 20…
Latest (Q to Jun 2026): Estimate −$2.28, Reported −$2.34.

The next report: what to expect → Inhibrx Biosciences: every quarter →

Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.